Rallybio is a private drug discovery company. It has raised $145 million across 1 recorded round; the latest was a $145 million Series B in May 2020.
PMV mark · valuation
—
Oct 2026
Last round
Early Stage VC (Series B)
May 2020
Investors — not yet on record
No investors in Rallybio are on record yet. Backers surface from round announcements, filings, and coverage sessions.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of Rallybio with a free account
- ·Watch Rallybio: the Monday email on marks, rounds and moves
